Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: March 12, 2024
Reporting Period: Specific event date (March 12, 2024); agreements effective January 1, 2024 (CEO) and March 11, 2024 (CFO).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes
The filing reports the execution of amended and restated employment agreements for the Chief Executive Officer and an amendment to the agreement for the Chief Financial Officer.
- CEO Agreement (Jeffrey Frelick):
- Effective Date: January 1, 2024.
- Base Salary: $300,000 annually.
- Annual Bonus: Targeted at 50% of base salary based on key performance indicators.
- Transaction Bonus: 1% to 2% of transaction value in the event of an acquisition.
- Severance: One year of base salary plus one year of insurance/COBRA if terminated without cause.
- Term: Automatically renewable for successive one-year periods unless notice of non-renewal is provided by July 9.
- CFO Agreement (Deina Walsh):
- Effective Date: March 11, 2024.
- Transaction Bonus: 0.5% to 1% of transaction value in the event of an acquisition.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary contingency noted is the potential for a change of control (acquisition), which triggers specific transaction bonuses for the CEO and CFO. Standard restrictive covenants, including non-competition and non-solicitation, are included in the CEO agreement.
Investor Verification Checklist
- Verify the total potential payout for the CEO and CFO under the new transaction bonus structures in the event of an acquisition.
- Confirm the terms of the automatic renewal clause for the CEO agreement and the specific notice deadline (July 9).
- Review the upcoming Form 10-Q for the quarter ending March 31, 2024, to obtain the full text of the Frelick Agreement and the CFO Amendment as referenced in the filing.
- Assess the impact of the 50% bonus target on future compensation expenses relative to the company's current cash position.